Publication:
Accuracy of pancreatic stone protein for the diagnosis of infection in hospitalized adults: a systematic review and individual patient level meta-analysis.

cris.virtual.author-orcid0000-0001-9443-6101
cris.virtualsource.author-orcid47e7580f-f500-46f6-b940-d755ef3d4b87
cris.virtualsource.author-orcid007b290f-0223-4af9-a46f-40052fc3a85a
cris.virtualsource.author-orcidce583f80-c3a5-4e4c-9e2d-acc1184e2bc9
datacite.rightsopen.access
dc.contributor.authorPrazak, Josef
dc.contributor.authorIrincheeva, Irina
dc.contributor.authorLlewelyn, Martin J
dc.contributor.authorStolz, Daiana
dc.contributor.authorGarcía de Guadiana Romualdo, Luis
dc.contributor.authorGraf, Rolf
dc.contributor.authorReding, Theresia
dc.contributor.authorKlein, Holger J
dc.contributor.authorEggimann, Philippe
dc.contributor.authorQue, Yok-Ai
dc.date.accessioned2024-09-02T17:32:18Z
dc.date.available2024-09-02T17:32:18Z
dc.date.issued2021-05-28
dc.description.abstractBACKGROUND Accurate biomarkers to diagnose infection are lacking. Studies reported good performance of pancreatic stone protein (PSP) to detect infection. The objective of the study was to determine the performance of PSP in diagnosing infection across hospitalized patients and calculate a threshold value for that purpose. METHODS A systematic search across Cochrane Central Register of Controlled Trials and MEDLINE databases (1966-March 2019) for studies on PSP published in English using 'pancreatic stone protein', 'PSP', 'regenerative protein', 'lithostatin' combined with 'infection' and 'sepsis' found 44 records. The search was restricted to the five trials that evaluated PSP for the initial detection of infection in hospitalized adults. Individual patient data were obtained from the investigators of all eligible trials. Data quality and validity was assessed according to PRISMA guidelines. We choose a fixed-effect model to calculate the PSP cut-off value that best discriminates infected from non-infected patients. RESULTS Infection was confirmed in 371 of 631 patients. The median (IQR) PSP value of infected versus uninfected patients was 81.5 (30.0-237.5) versus 19.2 (12.6-33.57) ng/ml, compared to 150 (82.70-229.55) versus 58.25 (15.85-120) mg/l for C-reactive protein (CRP) and 0.9 (0.29-4.4) versus 0.15 (0.08-0.5) ng/ml for procalcitonin (PCT). Using a PSP cut-off of 44.18 ng/ml, the ROC AUC to detect infection was 0.81 (0.78-0.85) with a sensitivity of 0.66 (0.61-0.71), specificity of 0.83 (0.78-0.88), PPV of 0.85 (0.81-0.89) and NPV of 0.63 (0.58-0.68). When a model combining PSP and CRP was used, the ROC AUC improved to 0.90 (0.87-0.92) with higher sensitivity 0.81 (0.77-0.85) and specificity 0.84 (0.79-0.90) for discriminating infection from non-infection. Adding PCT did not improve the performance further. CONCLUSIONS PSP is a promising biomarker to diagnose infections in hospitalized patients. Using a cut-off value of 44.18 ng/ml, PSP performs better than CRP or PCT across the considered studies. The combination of PSP with CRP further enhances its accuracy.
dc.description.numberOfPages10
dc.description.sponsorshipUniversitätsklinik für Intensivmedizin
dc.description.sponsorshipClinical Trials Unit Bern (CTU)
dc.identifier.doi10.48350/156629
dc.identifier.pmid34049579
dc.identifier.publisherDOI10.1186/s13054-021-03609-2
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/42220
dc.language.isoen
dc.publisherBioMed Central
dc.relation.ispartofCritical care
dc.relation.issn1364-8535
dc.relation.organizationDCD5A442BADDE17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BE42E17DE0405C82790C4DE2
dc.subjectBiomarker Infection PSP Pancreatic stone protein
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleAccuracy of pancreatic stone protein for the diagnosis of infection in hospitalized adults: a systematic review and individual patient level meta-analysis.
dc.typearticle
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.startPage182
oaire.citation.volume25
oairecerif.author.affiliationUniversitätsklinik für Intensivmedizin
oairecerif.author.affiliationClinical Trials Unit Bern (CTU)
oairecerif.author.affiliationUniversitätsklinik für Intensivmedizin
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2021-06-03 16:33:59
unibe.description.ispublishedpub
unibe.eprints.legacyId156629
unibe.journal.abbrevTitleCRIT CARE
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
2021_-_Prazak_-_Crit_Care_-_PMID_34049579.pdf
Size:
1.02 MB
Format:
Adobe Portable Document Format
License:
https://creativecommons.org/licenses/by/4.0
Content:
published

Collections